AMR Action Fund CEO Henry Skinner is quoted in a well-reported story about the slow pace of antimicrobial development and the regulatory and financial challenges facing biotechs in this space. "Most investors have blinders on and just view this as a dysfunctional market," he said. "Putting aside all the other challenges, which are real, how do you break through the perception that this is just a field you cannot touch as an investor?"
The Fund is also credited for its investment in Utility Therapeutics, which recently earned F.D.A. approval of the uncomplicated UTI drug Pivya (pivmecillinam).
Read the full story here.
